ADAGENE UNVEILS FIRST PATIENTS WITH ADVANCED NSCLC DOSED IN PHASE 1B/2 CLINICAL TRIAL OF ADG106

KUALA LUMPUR, Jan 14 (Bernama) -- Adagene Inc (Adagene) has announced that the first patients have been dosed in a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody, Nivolumab for patients with advanced non-small cell lung cancer (NSCLC) who have progressed on prior therapies.

The phase 1b/2 open label trial is designed to evaluate safety, tolerability, and anti-tumor activity of the combination in up to 53 patients with advanced NSCLC who have progressed after prior treatment.

According to a statement, the trial will also include exploratory biomarker analyses of a novel predictive biomarker and immune cell profiling in response to the treatment.

“This clinical trial is a key step in development of ADG106, which is being evaluated in combination with multiple anti-PD-1 therapies for synergistic T-cell stimulation that was shown in both preclinical and clinical studies in comparison with anti-CD137 monotherapy,” said Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene, Peter Luo, Ph.D.

“With the combination of these two independent, complementary pathways, ADG106 has the potential to overcome resistance to anti-PD-1 therapy, which remains a major limitation in the treatment of metastatic NSCLC.”

The clinical trial is being led by Professor Goh Boon Cher, Senior Consultant, Department of Hematology-Oncology and Deputy Director (Research) at NCIS, and Associate Professor Daniel Tan, Head of the Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, Division of Medical Oncology, NCCS.

Both Professor Goh and Associate Professor Tan lead the STCC’s Cancer Clinical Trials & Investigational Medicine Unit that brings together centers in Singapore for scaled up capacity, efficiency and expertise in conducting cancer clinical trials.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.

More details at https://investor.adagene.com.

-- BERNAMA